Lastly, it helps to avoid unnecessary examinations and interventions, ultimately increasing the efficiency and safety of prostate cancer diagnosis and therapy with radioactive PSMA ligands, thereby benefiting patients. This evidence concerns the gene FOLH1 and prostate cancer.